Replies to post #131 on Incyte Corporation (INCY)

[mlkrborn]

approved earlier.
# Monday, December 5, 10:44 AM Incyte (INCY -2.8%) trades lower after Citi cuts the shares the shares to Neutral from Buy. Citi cites limited market potential for Jakafi after conducting a survey that showed only 35% of physicians were expected to prescribe the drug to their patients. Comment! [On the Move, Healthcare]
# Wednesday, November 16, 11:29 AM Incyte (INCY) announces the FDA's approval of Jakafi, the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis. Trading halted. Comment! [Healthcare]
# Thursday, October 27, 8:31 AM Incyte (INCY): Q3 EPS of -$0.42 beats by $0.03. Revenue of $16.8M (-6% Y/Y) beats by $0.3M. (PR) Comment! [Earnings, Healthcare]
source: alpha

[mlkrborn]

approval and launching are both important:
http://www.fool.com/investing/high-growth/2011/11/17/in-biotech-approvals-important-but-its-the-launch.aspx